Curriculum Vitae - UNC Health Care · Curriculum Vitae September 1, 2019 Sascha Alexander Tuchman, M.D., M.H.S. Office information: University of North Carolina – Chapel Hill Comprehensive

Curriculum Vitae

September 1, 2019

Sascha Alexander Tuchman, M.D., M.H.S.

Office information:

University of North Carolina – Chapel Hill Comprehensive Cancer Center

Division of Hematology/Oncology

170 Manning Drive, CB# 7305

Chapel Hill, NC 27599

Office: 919-966-3856

Address of Clinical Investigation:

Clinical Protocol Office

Lineberger Comprehensive Cancer Center

450 West Drive CB 7295

3rd Flr Admin Tower

Chapel Hill, NC 27599

Office: 984-974-8659

Fax: 984-974-8564

Education

Master’s Degree in Health Sciences Clinical Research Training Program

Duke University School of Medicine

Durham, NC

2008 – 2016

Medical Doctorate Georgetown University School of

Medicine

Washington, DC

1998 – 2003

Bachelor of Science, and Tufts University

Bachelor of Arts Medford, MA

1992 – 1996

Certifications

Hematology 2010 - now

Medical Oncology 2010 - now

Internal Medicine 2006 - 2016

Medical Licensure

North Carolina # 2006-00516 2006- Present

Curriculum Vitae

September 1, 2019

Professional Experience

Associate Professor 2016 – now

Director, Multiple Myeloma and Amyloidosis Program

Division of Hematology and Oncology

Lineberger Comprehensive Cancer Center

University of North Carolina at Chapel Hill

Assistant Professor 2013 – 2016

Member, Plasma Cell Dyscrasias Program

Division of Cellular Therapy and Hematological Malignancies

Duke Cancer Institute

Medical Instructor 2010 – 2013

Duke Multiple Myeloma Program

Division of Medical Oncology


Fellow 2006 - 2010

Hematology and Medical Oncology


Resident and Chief Resident (2007-08) 2003 - 2008

Department of Internal Medicine

Duke University Medical Center

Honors and Awards


Selection as Eugene Stead Teaching Attending Physician 2012

Burroughs Wellcome Foundation Travel Award 2010

American Society of Hematology Travel Award 2009

American Society of Clinical Oncology Merit Award 2009

Georgetown University School of Medicine

Summa cum laude honors 2003

Milton Corn Scholarship (1st, 2nd, and 3rd Yrs) 2003

Thomas M. Kelliher Award for Excellence 2003

Murray Hammerman Grant 1998, 2002

Los Angeles Hillel Council Medical Scholarship 1999, 2000, 2001, 2002

Hattie M. Strong Foundation Scholarship 2002

Emanuel Sternberger Memorial Scholarship 1999, 2001, 2002

Curriculum Vitae

September 1, 2019

Bill Raskob Memorial Scholarship-Loan 2001, 2002

Evalee C. Schwarz Memorial Scholarship-Loan 2001, 2002

Samuel F. and Sara G. Feinman Fund Scholarship-Loan 2001, 2002

Albert Strickler Memorial Scholarship 1999, 2002

J. William Fulbright Scholarship for Study at Humboldt Univ. in Berlin, Germany 1996-1997

Books and Chapters

Rosko A, Bhatt G, Lichtman E, and Tuchman SA. Multiple myeloma in older adults. Geriatric

Oncology. 2018.

Guerard EJ, Tuchman SA. Monoclonal gammopathy of undermined significance and multiple

myeloma in older adults. Clinics in Geriatric Medicine. 2015 32(1):191-205.

Olyaei AJ, Lerma E, Tuchman SA, Sparks M. Rational chemotherapy dosing in patients with

CKD. Onconephrology: Cancer, Chemotherapy and the Kidney. 2015.

Refereed Papers/Articles

Chari A, Vogl T, Gavriatopoulou M, Nooka A, Yee A, Huff C, Moreau P, Dingli D, Cole C,

Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman SA…, Richardson P, and

Jagganath S. Oral Selinexor/Dexamethasone for Triple-Class Refractory Multiple Myeloma.

New Eng J Med. 2019; 381:727-738.

Freeman A, Kuo T, Zhou L, Trogdon J, Baggett C, Tuchman SA, Shea T, Wood W. Influence of

treating facility, provider volume and patient sharing on survival of patients with multiple

myeloma. J Natl Comp Can Network. Accepted for publication 2019.

Isaacs A, Fiala M, Tuchman SA and Wildes TW. A Comparison of Three Different Approaches

to Defining Frailty in Older Patients with Multiple Myeloma. J Geriatr Oncol 2019;

https://doi.org/10.1016/j.jgo.2019.07.004

Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, Lichtman E, Tuchman SA, Dotti G,

Savoldo B. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the

treatment of multiple myeloma. Oncotarget 2019; 10:2369-

2383. https://doi.org/10.18632/oncotarget.26792

Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl-Goldstein K, Vij R &

Colditz G. Geriatric Assessment in Older Adults with Multiple Myeloma. J Am Geriatr Soc 2018

Dec 13. doi.org/10.1111/jgs.15715

https://doi.org/10.18632/oncotarget.26792

Curriculum Vitae

September 1, 2019

Schepers AJ, Jones AR, Reeves BN, Tuchman SA, Bates JS. A comparison of response in the

presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and

dexamethasone. J Oncol Pharm Pract. 2018 Nov 30:1078155218815283. doi:

10.1177/1078155218815283. PMID: 30501382.

Cotton SW, Shajani-Yi Z, Cervinski MA, Voorhees T, Tuchman SA, Korpi-Steiner N. Reference

intervals and diagnostic ranges for serum free kappa and free lambda immunoglobulin light chains

vary by instrument platform: Implications for classification of patient results in a multi-center

study. Clin Biochem 2018. Doi: 10.1016/j.clinbiochem.2018.06.003.

Fakhri B, Fiala M, Tuchman, SA, Wildes TM. Undertreatment of Older Patients with Newly

Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clin Lymph Myel Leuk 2018. doi:

10.1016/j.clml.2018.01.005.

Fiala M, Dukeman J, Tuchman SA, Keller M, Vij R, Wildes TM. Development of an Algorithm

to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets.

JCO Clinical Cancer Informatics 2017. doi: 10.1200/CCI.17.00089.

Tuchman SA, Moore JO, DeCastro CD, Li Z, Sellars E, Kang Y, Long G, Gasparetto CG. Phase

II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in

very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. J Geri

Oncol. Epub 2017. doi: 10.1016/j.jgo.2017.02.004.

Huang LW, Bacon W, Cirrincione C, Peterson B, Long G, Rizzieri D, Sullivan KM, Corbet K,

Horwitz M, Chao N, Gasparetto C, Tuchman SA. Efficacy and safety of high-dose chemotherapy

with autologous stem cell transplantation in senior versus younger adults with newly diagnosed

multiple myeloma. Hematol Oncol. 2017 doi: 10.1002/hon.2379.

Reeves B and Tuchman SA. Management of relapsed and refractory multiple myeloma. J Clin

Outcomes Management 23(10) 2016.

LeBlanc TW, Howson A, Turell W, Sheldon P, Locke SC, Tuchman SA, Gasparetto C, Kaura S,

Khan ZM, Abernethy AP. Risk stratification, treatment selection, and transplant eligibility in

multiple myeloma: a qualitative study of the perspectives and self-reported practices of

oncologists. Curr Oncol. 2016 23(6):e598-e604. doi: 10.3747/co.23.3298.

Dupuis MM, Tuchman SA. Non-secretory multiple myeloma: from biology to clinical

management. Onco Targets Ther. 2016 9:7583-7590. doi: 10.2147/OTT.S122241. eCollection

2016.

Tuchman SA, Lane A, Hornesby WE, Bishop C, Thomas S, Herndon JE, Long G, Gasparetto C,

Jones LW. Quantitative measures of physical functioning after autologous hematopoietic stem

cell transplantation in multiple myeloma: A feasibility study. Clin Lymph Myel Leuk 2014

15(2):103-9.

Curriculum Vitae

September 1, 2019

Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, Chute J, Sullivan K,

Engemann AM, Yopp A, Li Z, Corbett K, Chao N, Gasparetto C. Cyclophosphamide-based

hematopoietic stem cell mobilization prior to autologous stem cell transplantation in newly

diagnosed multiple myeloma. J Clin Apheresis. 2014 30(3):176-82.

Wildes TW, Rosko A, Tuchman SA. Multiple myeloma in older adults: Better prospects, more

challenges. J Clin Oncol. 2014 32(24):2531-40.

Tuchman SA, Shapiro GR, Ershler WB, Badros A, Cohen HJ, Dispenzieri A, Flores IQ, Kanapuru

B, Hesdorffer C, Longo DL, Nourbakhsh A, Palumbo A, Walston J, Yates JW. Multiple myeloma

in the very old: An IASIS conference report. J Natl Canc Inst. 2014 106(5):1-9.

Tuchman SA, Chao N, Gasparetto C. Lenalidomide before and after autologous hematopoietic

stem cell transplantation in multiple myeloma. Adv Hematol. 2012. 2012:712613. Epub 2012

May 30.

Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA,

Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Retraction: Characterizing the clinical

relevance of an embryonic stem cell phenotype in the lung adenocarcinoma. Clin Cancer Res 2009

15(24):7553-7561.

Acharya C, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman

SA, Moylan CA, Mukherjee S, Barry W, Dressman H, Ginsburg G, Marcom PK, Garman K,

Lyman G, Nevins J, Potti A. Retraction: Gene Expression Signatures, Clinicopathological features

and individualized therapy. JAMA 2008 299(13):1574-87.

Tuchman SA, Lonial S. High-risk multiple myeloma: Does it still exist? Clin Lymphona

Myeloma Leuk 2011. 11(1):S70-76.

Rao AV, Valk PJ, Metzeler KH, Acharya C, Tuchman SA, Stevenson M, Rizzieri DA, Delwel R,

Buske C, Bohlander SK, Potti A, Lowenberg B. Age-specific differences in oncogenic pathway

dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol.

2009 27(33):5580-6. Erratum in 2012 27(33):5580.

Anguiano A, Tuchman SA (co-first authors), Acharya A, Salter K, Gasparetto C, Zhan F,

Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD, Potti A. Gene expression profiles of tumor

biology provide a novel approach to prognosis and guide the selection of therapeutic targets in

multiple myeloma. J Clin Oncol 2009 27(25):4197-4203. Erratum in 2012 30(5):572.

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman SA,

Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. Characterizing the

Curriculum Vitae

September 1, 2019

developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Nat Acad Sci 2009

106(13):5313-7. Erratum in Proc Nat Acad Sci 2011 108(35);14705.

Potti A, Tuchman SA, Ganti AP, Sholes K, Langness E, Koka V, Koch M. HER-2 neu and CD117

(c-kit) overexpression in patients with pesticide exposure and extensive stage small cell carcinoma.

J Carcinog 2005 June 9; 4:8.

Hematti P, Tuchman SA, Larochelle A, Metzger ME, Donahue RA, Tisdale JF. Comparison of

Retroviral Transduction Efficiency in CD34+ Cells Derived from Bone Marrow versus G-CSF

and G-CSF+SCF Mobilized Peripheral Blood in Non-Human Primates. Stem Cells

2004;22(6):1062-9.

Un-Refereed Article

Tisdale JF, Tuchman SA, Wu T, Kim HJ, Sellers SE, Kang EM, Donahue RA, Dunbar CE.

Optimization of hematopoietic stem cell gene transfer methods using the non-human primate

competitive repopulation model: Recent progress toward clinical application. Autologous Blood

and Marrow Transplantation X: Proceedings of the 10th Intl. Symposium. Carden Jennings

Publishing Co. 2001.

Letter to the Editor

Huang LW, Tuchman SA. Re: intrathecal vincristine as mentioned in ‘overview of recent trends

in diagnosis and management of leptomeningeal multiple myeloma’ Hematol Oncol 34:224, 2015.

Recent Conference Abstracts

White D, Leblanc R, Venner C, Bahlis NJ, Lentzsch S, Gasparetto C, Chen C, Lipe B, Sutherland

H, Tuchman SA… Schillar G. Safety and Efficacy of the Combination of Selinexor,

Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed / Refractory Multiple

Myeloma (RRMM). Intl Myeloma Workshop 2019.

Usmani S, Karanes C, Bensinger WI, D’Souza A, Raje N, Tuchman SA, Sborov D, Kanagavel

D, Dublin F, Campana F and Richardson PG. Isatuximab short duration fixed volume infusion

combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b

feasibility/safety study. Intl Myeloma Workshop 2019. Gasparetto CG, Lentzsch S, Schiller G, Callander N, Tuchman SA…, Lipe B. Safety and Efficacy

of Combination of Selinexor, Daratumumab and Dexamethasone (SDD) in Patients with Multiple

Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs.

EHA Library 2019. (suppl; abstr S1606).

Curriculum Vitae

September 1, 2019

Chen C, Gasparetto C, White D, Kotb R, Lipe B, Sutherland H, Sebag M, Tuchman SA… Bahlis

N. Selinexor, Pomalidomide and Dexamethasone (SPD) in Patients with Relapsed or Refractory

Multiple Myeloma. EHA Library 2019. (suppl; abstr PF587).

Usmani S, Karanes C, Bensinger W, D’Souza A, Raje N, Tuchman SA… Richardson P.

Preliminary Data: Phase 1B Study of Feasibility / Safety of Isatuximab Short Duration Fixed

Volume Infusion in Combination with Pomalidomide and Dexamethasone for Relapsed /

Refractory Multiple Myeloma. EHA Library 2019. (suppl; abstr PS1390).

Chari A, Vogl D…Tuchman SA…Jagannath S. Results of the Pivotal STORM Study (Part 2) in

Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus

Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM.

Blood 2018. (suppl; abstr 598).

Wood WA, Freeman A, Zhou L, Kuo TM, Trogdon JG, Baggett CD, Tuchman SA, and Shea TC.

Access to NCI Comprehensive Cancer Centers among Patients with Multiple Myeloma: An

Opportunity to Address Transplant Underutilization and Long Term Outcomes. Biol Blood

Marrow Transplantation 2018 (suppl; abstr 79).

Dupuis MM, Li Z, Tuchman SA and Kang Y. The Gamma Gap: A Point-of-Care Test That

Correlates with Disease Burden and Treatment Response in Multiple Myeloma. Blood 130:4407,

2017 (suppl: abstr 4407).

Freeman AT, Zhou L, Trogdon JG, Baggett CD, Tuchman SA, Shea TC and Wood WA. Impact

of NCI Comprehensive Cancer Center Designation, Provider Specialization and Patient Sharing

with Community Providers on Outcomes for Patients with Multiple Myeloma. Blood 130:529,

2017 (suppl: abstr 529).

Zonder,JA, Sanchorawala V, Kukreti,V, Tuchman SA, Kang Y, Bhutani D, Burt S, Houde C,

Reichel KA, Pregja S, and Matous JV. Phase I Trial of Pomalidomide, Bortezomib, and

Dexamethasone As Frontline Treatment of AL Amyloidosis. Blood 130:3158, 2017 (suppl: abstr

3158).

Teaching / Mentoring Activities

Mentoring

2017-now: Christopher Dittus, DO, MPH, Currently assistant professor, UNC – Chapel Hill

(secondary mentor)

2017-now: Timothy Voorhees, MD, Currently hematology/oncology fellow, UNC – Chapel Hill

(secondary mentor)

2016-now: Brandi Reeves, MD, Currently assistant professor, UNC – Chapel Hill (co-primary

mentor)

Curriculum Vitae

September 1, 2019

2016-now: Eben Lichtman, MD, Currently assistant professor, UNC – Chapel Hill (primary

mentor)

2015-2016: Megan Dupuis, MD PhD, Currently hematology/oncology fellow, MD Anderson

Cancer Center (secondary mentor)

2014-2016: Li-Wen Huang, MD, Currently hematology/oncology fellow, UCSF (primary research

mentor)

Recent Grand Rounds / Invited Speaking Engagements:

Geriatrics Grand Rounds, UNC (CME) – Chapel Hill, February 8, 2019

“Multiple Myeloma and Amyloidosis in Seniors”

Untangling Amyloidosis, American Society of Hematology Annual Meeting (CME) Satellite

Symposium - San Diego, CA, November 29, 2018

“RNA Therapies in TTR Amyloidosis”

Internal Medicine Grand Rounds (CME), UNC – Chapel Hill, May 14, 2018

“Amyloidosis, Cyanide, Myeloma and Ethanol: Conceptualizing Paraprotein-Mediated

Renal Diseases”

Grand Rounds (CME), FirstHealth – Pinehurst, NC, November 9, 2017

“Updates in Multiple Myeloma”

Nephrology Grand Rounds, UNC (CME) – Chapel Hill, October 25, 2017

“Paraproteins and the Kidneys”

Glomerular Diseases Collaborative Network, UNC – Chapel Hill, May 7, 2017

“Amyloidosis and other forms of monoclonal gammopathy of renal significance”

Hematology / Oncology Grand Rounds, Duke University, June 1, 2016

“How I treat multiple myeloma: 2016 edition”

Hematology / Oncology Grand Rounds, UNC – Chapel Hill, March 6, 2016

“Multiple myeloma in the frail and elderly”

Nephrology Grand Rounds, Duke University, January 2015

“Monoclonal gammopathy of renal significance and other plasma cell dyscrasias”

Student Teaching:

Cancer Care Experience faculty mentor, Duke University, 2014-2016

Undergraduate Pre-Health Professions Advisory Program faculty mentor, Duke University, 2014-

2016

Hematology / Medical Oncology Fellow Teaching:

Multiple myeloma and amyloidosis – hematology/oncology fellow core curriculum, 2017 - now

Paraproteins and the Kidneys – Duke nephrology fellow core curriculum, 2016 – now

“Multiple myeloma” – annual case-based session as part of fellows’ core curriculum, Duke

University, 2014-2016

Curriculum Vitae

September 1, 2019

GRANTS AND OTHER SUPPORT

Active

TCD14079: Phase 1b study of isatuximab in combination with pomalidomide and dexamethasone

in relapsed / refractory multiple myeloma

Role: Site principal investigator

Funding source: Sanofi

November 2018 - ongoing

KCP-330-017 STOMP: Selinexor in combination with backbone treatments in multiple myeloma


Funding source: Karyopharm Pharmaceuticals, Inc.

November 2018 - ongoing

S1702: Isatuximab in relapsed or refractory light chain amyloidosis


Funding source: Alliance Cooperative Cancer Research Group

September 2018 - ongoing

KCP-330-012 STORM: Phase 2b study of selinexor in penta-refractory multiple myeloma


Funding source: Karyopharm Pharmaceuticals, Inc.

2017 – ongoing

A106062: ALLIANCE randomized clinical trial of pomalidomide + dexamethasone +/- ixazomib

for relapsed and refractory multiple myeloma


2016 – ongoing

Targeting CD138 in myeloma (chimeric antigen receptor-T [CAR-T]) phase 1 study

Role: Principal investigator

Funding source: Lineberger Comprehensive Cancer Center

2016 - ongoing

INCB001158 plus daratumumab phase 1/2 study in relapsed / refractory multiple myeloma


2019 - ongoing

CALGB 100104: Lenalidomide maintenance after autologous hematopoietic stem cell transplant

for multiple myeloma


2019 – ongoing

Curriculum Vitae

September 1, 2019

EAA173: Daratumumab plus revlimid in smoldering myeloma


2019 – ongoing

Pending

S1803: Phase III study of daratumumab + lenalidomide or lenalidomide as post-autologous stem

cell transplant maintenance therapy in multiple myeloma


Anticipated opening late 2019

Terminated

NP39403: Open label dose escalation / expansion phase 1b of R06870810 in multiple myeloma


Funding source: Genentech

2017 – 2019

VITAL: Randomized controlled trial of NEOD001 vs placebo in addition to standard

chemotherapy for newly diagnosed AL amyloidosis with cardiac involvement


Funding source: Prothena Pharmaceuticals, Inc.

2015-2017

KEYNOTE-185: Randomized controlled trial of lenalidomide and dexamethasone +

pembrolizumab or placebo for newly diagnosed multiple myeloma in non-transplant candidates


Funding source: Merck

2017 – 2017 (trial was terminated same year)

APOLLO: Randomized controlled trial of patisiran vs placebo in familial amyloid polyneuropathy


Funding source: Alnylam Pharmaceuticals, Inc.

2014 – August 2016

Investigator-Initiated Trial: Subcutaneous bortezomib and oral cyclophosphamide-based induction

followed by sequential maintenance therapy with bortezomib and lenalidomide for newly

diagnosed multiple myeloma in non-transplant candidates: An entirely non-intravenous regimen

Role: Study-wide principal investigator

Funding source: Millennium Pharmaceuticals, Inc.

November 2012 – August 2016

Curriculum Vitae

September 1, 2019

Geriatric assessment in senior adults with multiple myeloma. (Investigator-initiated trial by Tanya

Wildes, MD, Washington University School of Medicine)


January 2014 – August 2016

Pomalidomide, bortezomib and dexamethasone for patients with newly diagnosed AL amyloidosis

or light chain deposition disease


July 2014 – August 2016

Panobinostat, lenalidomide, bortezomid and dexamethasone for relapsed and refractory multiple

myeloma


August 2014 – August 2016

PRONTO: Randomized controlled trial of NEOD001 vs placebo for AL amyloid with residual

cardiac involvement after chemotherapy


Funding source: Prothena Pharmaceuticals, Inc.

May 2016 – August 2016

Optimizing novel therapeutics for multiple myeloma

Role: Clinical researcher and trainee

Principal investigator: Robert Califf, M.D.

Mentored Clinical Research Scholar Program of the Duke University Translational

Medicine Institute

KL2 RR024127

July 2010 – July 2013

Novel therapeutic approaches may improve outcomes while mitigating toxicity and enhancing

patient convenience in multiple myeloma


NIH Clinical Research Loan Repayment Program

October 2010 – July 2013

Phase II clinical trial: BHQ880 in high-risk smoldering myeloma


Novartis sponsored trial

July 2012 – December 2012

The type III transforming growth factor β receptor in progression of multiple myeloma


Barton F. Haynes Research Award

Curriculum Vitae

September 1, 2019

July 2010 – June 2011

Oncogenic pathway analysis for individualized therapy in multiple myeloma


American Society of Hematology Research Training Award for Fellows

July 2009 – June 2010

Non-human primate studies of gene transfer for beta-globinopathies

Role: Principal investigator, medical student research trainee

Howard Hughes Medical Institute – NIH Research Scholars Grant (the “Cloister” Program)

July 2000 – July 2001

Study of German literature and German-English interpreting, and teaching English in former East

Berlin high school

Role: Principal investigator, visiting scholar

J. William Fulbright Grant

July 1996 – September 1997

PROFESSIONAL SERVICE

Editorial Review

Amyloid Ad hoc; 2019 - Current

J of Oncology Practice Ad hoc; 2019 - Current

Oncotargets and Therapy Ad hoc; 2018 - Current

Clinical Epidemiology Ad hoc; 2018 – Current

J Clin Apheresis Ad hoc; 2017 – Current

Journal of Geriatric Oncology Ad hoc; 2016 - Current

Cancer Ad hoc; 2015 - Current

Bone Marrow Research Ad hoc; 2011 - Current

Clinical Lymphoma, Myeloma and Leukemia Ad hoc; 2011 - Current

Journal of the American Medical Association Ad hoc; 2015

Expert Review of Hematology Ad hoc; 2014

Drugs of the Future Ad hoc; 2014

Expert Opinion on Biological Therapy Ad hoc; 2013

Experimental Hematology & Oncology Ad hoc; 2012

Committees, Societies, and Memberships

Member

Patient Discovery Amyloidosis Appointment Companion Steering Group

September 2019 – now

Member

Curriculum Vitae

September 1, 2019

Steering Committee

Amyloidosis Research Consortium

August 2019 – now

Chair

Compliance Committee

Lineberger Comprehensive Cancer Center at UNC – Chapel Hill

June 2019 – now

Member

Cancer Conversations Advisory Board

Lineberger Comprehensive Cancer Center at UNC – Chapel Hill

2018 – now

Member

Oncology Governance Committee

North Carolina Cancer Hospital, UNC – Chapel Hill

2018 – now

Physician Lead

Lineberger Clinical Protocols Office, UNC Affiliate Network Research Initiative

2018 – now

Member

Hoosier Cancer Research Network Multiple Myeloma Clinical Trial Working Group

2017 – Current

Member

Cancer in the Elderly Committee

Alliance for Clinical Trials in Oncology

2017 – Current

Member

International Kidney and Monoclonal Gammopathy Research Group

2016 – Current

Member

International Myeloma Working Group

2016 – Current

Founding Member

Myeloma in the Elderly Subcommittee


Curriculum Vitae

September 1, 2019

2015 – Current

Member

Multiple Myeloma Committee


2014 – Current

Member

Lineberger Comprehensive Cancer Center Clinical Protocols Office Clinical Trials Executive

Committee

2016 – Current

Member

International Society of Amyloidosis

2013 – Current

Carolinas Amyloidosis Patient Support Group

Organizer / Host of yearly February meeting at UNC – Chapel Hill

2013 – Current

Member

American Society of Hematology

2006 - Current

Grant reviewer

Untangling Amyloidosis Symposium, American Society of Hematology

October 2019

Member

Independent Review Committee (IRC)

HORIZON OP-106 clinical trial of melflufen in relapsed and refractory multiple myeloma

Oncopeptides

August – September 2019

Laboratory Process Improvement Committee

NC Cancer Hospital

Physician Team Lead

2017 – 2019

Member

Lineberger Comprehensive Cancer Center Clinical Protocols Office Resource and Feasibility

Team (RAFT) Committee

2017 – July 2019

Curriculum Vitae

September 1, 2019

A3 Nurse Navigator and Trial Coordinator Roles and Responsibilities Committee

NC Cancer Hospital

Committee Member

2017- 2018

Member

Lineberger Comprehensive Cancer Center – UNC – Chapel Hill Data Safety Monitoring

Committee

2017 – 2018

Duke Cancer Institute Geriatric Oncology

Leadership Committee Member

2013 – 2016


Institutional Review Board Member

2011 – 2016

Duke University Medical Cancer Center

Protocol Committee Member

2011 – 2012

Duke University Medical Center Hematology/Oncology

Fellowship Committee, fellows’ representative

2009 – 2010

American Association of Cancer Research

Associate Member

2009 – 2013

Duke University Medical Center Department of Medicine

Graduate Medical Education Committee

2007 – 2008

Duke University Medical Center Library

Committee Member

2007 – 2008

American Society of Clinical Oncology

Member

2006 – 2012

Curriculum Vitae

September 1, 2019

Research Statement

My research agenda focuses broadly on plasma cell malignancies and encompasses three major

aims: 1) Optimizing therapy for frail and/or very senior adults with the incurable cancer multiple

myeloma (MM); 2) Developing new therapies for all patients with MM, and 3) Developing new

therapies for all patients with amyloidosis. As for #1, MM is primarily a cancer of the elderly, yet

most MM studies are conducted in younger, healthy adults. There is a dearth of knowledge

regarding how to optimize existing therapies to make treating MM in seniors both effective and

tolerable. Much of my research focuses on clinical trials, and specifically using novel instruments

such as geriatric assessment to predict chemotherapy toxicity, with the longer-term aim of then

using such data to select therapies of appropriate intensity for any given patient. Additionally, I

am interested in the extensive intersection between the biology of aging and the biology of MM,

and am beginning work with laboratory-based collaborators to see if that biology can be targeted

in a manner that helps with both conditions. As for aim #2, many new drugs are available for MM

and others are coming. I work closely with both industry and academic sponsors to design and

conduct early (phase I/II) and later phase clinical trials to test new medications, or new

combinations of older medications. In terms of aim #3, amyloidosis is a rare and in many cases

fatal disease, and therapy is inadequately effective and difficult to tolerate. My amyloidosis work

also involves clinical trials examining new drug and drug combinations aimed at improving

outcomes in this difficult disease.

Teaching Statement

As a practicing malignant hematologist with an active clinical research program, I teach learners

by working with them in the context of both my roles. Clinically, students and post-graduate

medical trainees (interns, residents, and hematology/oncology fellows) join me on hospital rounds

and in my plasma cell diseases outpatient clinic. Students may just shadow me, whereas more

advanced trainees see my patients and devise diagnostic and management plans. We then review

those plans and use them as a platform for learning, either discussing specific elements of how

they managed a particular patient, or in a more lecture-based format to cover relevant topics more

comprehensively. In terms of research mentorship, over the years I have mentored and continue

mentoring several internal medicine residents and fellows in conducting clinical research projects.

I assist with formulating the research question, designing a research plan, collecting and analyzing

data, and preparing for presentations and publications. My mentees in the past have presented at

national meetings and published manuscripts based on our work together.

Documents

Curriculum Vitae - UNC Health Care · Curriculum Vitae September 1, 2019 Sascha Alexander Tuchman, M.D., M.H.S. Office information: University of North Carolina – Chapel Hill Comprehensive